Vancouver, British Columbia – February 18, 2015 – Sirona Biochem Corp. (TSX-V: SBM / FSE: ZSB) announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO Europe in Paris, France, on March 11th at 11:30AM GMT at the Paris Expo – Porte de Versailles.
The presentation will include safety and efficacy results of the new skin lightener TFC-1067, the glycoprotein program for anti-aging and regenerative medicine, as well as updates from the SGLT2 inhibitor program that is currently under license agreement with Wanbang Biopharmaceuticals – headquartered in the Peoples Republic of China. All results will be released publicly prior to the presentation.
Major companies attending the conference include Johnson & Johnson, GSK, Pfizer and many others. Sirona Biochem Senior Management will be attending other international partnering meetings and events in the near future as the company continues its business objective of licensing its world class platform technology.
About BIO Europe
BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities.
BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at http://www.ebdgroup.com/bes
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.